ATE520712T1 - Antiangiogene verbindungen - Google Patents

Antiangiogene verbindungen

Info

Publication number
ATE520712T1
ATE520712T1 AT07827123T AT07827123T ATE520712T1 AT E520712 T1 ATE520712 T1 AT E520712T1 AT 07827123 T AT07827123 T AT 07827123T AT 07827123 T AT07827123 T AT 07827123T AT E520712 T1 ATE520712 T1 AT E520712T1
Authority
AT
Austria
Prior art keywords
compounds
antiangiogenic compounds
targeting
antibody
linked
Prior art date
Application number
AT07827123T
Other languages
German (de)
English (en)
Inventor
Curt Bradshaw
Abhijit Bhat
Jing-Yu Lai
Venkata Doppalapudi
Dingguo Liu
Original Assignee
Covx Technologies Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covx Technologies Ireland Ltd filed Critical Covx Technologies Ireland Ltd
Application granted granted Critical
Publication of ATE520712T1 publication Critical patent/ATE520712T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT07827123T 2006-11-10 2007-11-12 Antiangiogene verbindungen ATE520712T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86536006P 2006-11-10 2006-11-10
US93983007P 2007-05-23 2007-05-23
US94532907P 2007-06-20 2007-06-20
PCT/IE2007/000110 WO2008056346A2 (en) 2006-11-10 2007-11-12 Anti-angiogenic compounds

Publications (1)

Publication Number Publication Date
ATE520712T1 true ATE520712T1 (de) 2011-09-15

Family

ID=39364902

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07827123T ATE520712T1 (de) 2006-11-10 2007-11-12 Antiangiogene verbindungen

Country Status (18)

Country Link
US (3) US8288349B2 (https=)
EP (2) EP2089425B1 (https=)
JP (2) JP4897050B2 (https=)
KR (2) KR101309948B1 (https=)
CN (1) CN101611053B (https=)
AT (1) ATE520712T1 (https=)
AU (1) AU2007318912B2 (https=)
BR (1) BRPI0718591A2 (https=)
CA (1) CA2669207A1 (https=)
DK (1) DK2089425T3 (https=)
IL (1) IL198581A (https=)
MX (1) MX2009005045A (https=)
MY (1) MY146985A (https=)
NO (1) NO20092203L (https=)
NZ (1) NZ576751A (https=)
PL (1) PL2089425T3 (https=)
PT (1) PT2089425E (https=)
WO (1) WO2008056346A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2089425B1 (en) * 2006-11-10 2011-08-17 CovX Technologies Ireland Limited Anti-angiogenic compounds
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
US8293714B2 (en) * 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
WO2010036930A1 (en) * 2008-09-26 2010-04-01 Javad Parvizi Methods and kits for detecting joint infection
WO2012007896A1 (en) * 2010-07-12 2012-01-19 Covx Technologies Ireland, Ltd. Multifunctional antibody conjugates
JP2014500248A (ja) * 2010-11-05 2014-01-09 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗糖尿病化合物
MX358726B (es) 2011-06-29 2018-09-03 Amgen Inc Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales.
BR112014015141A2 (pt) 2011-12-20 2020-10-27 Pfizer Inc. processos aperfeiçoados para preparação de conjugados e ligantes de peptídeo
TW201341401A (zh) 2012-01-09 2013-10-16 Covx Technologies Ireland Ltd 突變抗體及其共軛
EP2831116A1 (en) 2012-03-28 2015-02-04 Amgen Inc. Dr5 receptor agonist combinations
ES2699576T3 (es) 2013-06-12 2019-02-11 Pharis Biotec Gmbh Péptidos con actividades antagonistas contra CXCR4 natural
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
ES2826398T3 (es) 2013-10-15 2021-05-18 Seagen Inc Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco
WO2016209972A1 (en) 2015-06-26 2016-12-29 Amgen Inc. Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
CN108367043A (zh) 2015-12-04 2018-08-03 西雅图基因公司 季铵化的微管溶素化合物的缀合物
KR20180134351A (ko) 2016-03-25 2018-12-18 시애틀 지네틱스, 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
CN110637027B (zh) 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
AU2018237683A1 (en) 2017-03-24 2019-10-31 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
EP3617235B1 (en) 2017-04-28 2026-02-18 Ajinomoto Co., Inc. Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5216132A (en) 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
WO1991015515A1 (en) 1990-04-06 1991-10-17 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US6080840A (en) 1992-01-17 2000-06-27 Slanetz; Alfred E. Soluble T cell receptors
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5733757A (en) * 1995-12-15 1998-03-31 The Scripps Research Institute Aldolase catalytic antibody
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6326176B1 (en) * 1997-12-18 2001-12-04 The Scripps Research Institute Aldol condensations by catalytic antibodies
JP2003516121A (ja) 1999-09-27 2003-05-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 不可逆的に結合するエンジニアリング抗体
US6294374B1 (en) * 1999-10-08 2001-09-25 The Scripps Research Institute Use of catalytic antibodies for synthesizing epothilone
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US20030045477A1 (en) 2001-07-26 2003-03-06 Fortuna Haviv Peptides having antiangiogenic activity
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
EP1443963B1 (en) * 2001-10-22 2014-05-21 The Scripps Research Institute Antibody targeting compounds
US6737524B2 (en) * 2002-03-25 2004-05-18 Paul K. Smith Activated polyethylene glycol compounds
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
AU2003290330A1 (en) 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
WO2006010057A2 (en) * 2004-07-08 2006-01-26 Amgen Inc. Therapeutic peptides
EA011879B1 (ru) * 2004-09-24 2009-06-30 Эмджин Инк. МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ
EP2089425B1 (en) * 2006-11-10 2011-08-17 CovX Technologies Ireland Limited Anti-angiogenic compounds

Also Published As

Publication number Publication date
PT2089425E (pt) 2011-10-17
US20150057431A1 (en) 2015-02-26
CN101611053B (zh) 2015-06-03
NO20092203L (no) 2009-08-10
US20120301431A1 (en) 2012-11-29
IL198581A (en) 2015-10-29
EP2368908A3 (en) 2011-10-12
WO2008056346B1 (en) 2008-12-04
AU2007318912B2 (en) 2011-03-03
AU2007318912A1 (en) 2008-05-15
EP2368908A2 (en) 2011-09-28
EP2089425B1 (en) 2011-08-17
KR101309948B1 (ko) 2013-09-23
MY146985A (en) 2012-10-15
JP2010509315A (ja) 2010-03-25
EP2089425A2 (en) 2009-08-19
WO2008056346A2 (en) 2008-05-15
JP2012121886A (ja) 2012-06-28
MX2009005045A (es) 2009-11-10
PL2089425T3 (pl) 2012-02-29
BRPI0718591A2 (pt) 2013-12-03
KR20090090331A (ko) 2009-08-25
JP4897050B2 (ja) 2012-03-14
CN101611053A (zh) 2009-12-23
WO2008056346A3 (en) 2008-10-23
US8912148B2 (en) 2014-12-16
US20080166364A1 (en) 2008-07-10
IL198581A0 (en) 2011-08-01
KR20120043028A (ko) 2012-05-03
US8288349B2 (en) 2012-10-16
CA2669207A1 (en) 2008-05-15
NZ576751A (en) 2011-10-28
DK2089425T3 (da) 2011-10-10

Similar Documents

Publication Publication Date Title
ATE520712T1 (de) Antiangiogene verbindungen
WO2006094269A3 (en) Anti-angiogenic compounds
DOP2012000038A (es) Conjugados de dímeros de pirrolo [1,4] benzodiazepina como agentes anticancerosos
MX2009007146A (es) Conjugados porcion del factor ix-polimero que tienen ligadura que se puede liberar.
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
CL2007003854A1 (es) Compuestos derivados de ciclopamina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto, util en el tratamiento de desordenes mediados por la via de hedgehog, como cancer.
HN2006000668A (es) Compuestos de quinolina heteroaromaticos
CY1119077T1 (el) Παραγωγα πυραζολυλαμινοπυριδινης χρησιμα ως αναστολεις κινασων
EA201200486A1 (ru) Лечение онкологических заболеваний
SE0202241D0 (sv) Novel Compounds
EA201270049A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
WO2009051670A3 (en) Oxylipin compounds for the treatment of ophthalmic conditions
GB2466912A (en) Compositions and methods for treating lysosomal disorders
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
WO2007138282A3 (en) Bi-aryl or aryl-heteroaryl substituted indoles
EA201270818A1 (ru) 6-(1-МЕТИЛ-1H-ПИРАЗОЛ-4-ИЛ)-3-(2-МЕТИЛ-2H-ИНДАЗОЛ-5-ИЛТИО)-[1,2,4]ТРИАЗОЛ-[43-b]ПИРИДАЗИН В КАЧЕСТВЕ ИНГИБИТОРА c-МЕТ
EA201170699A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
DOP2010000302A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
EA201170640A1 (ru) Дизамещенные фталазины-антагонисты сигнального пути hedgehog
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
EA201170700A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
NO20074047L (no) Ny fremgangsmate for fremstilling av substituerte indoler
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
WO2010077310A3 (en) Amide derivatives of ethacrynic acid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2089425

Country of ref document: EP